Tri-Heal (45 mg Blend)

Tri-Hea Overview

Tri-Heal is administered at 500 mcg–2 mg daily via subcutaneous administration in educational protocols. A 45 mg blend reconstituted with bacteriostatic water yields about 15 mg/mL. This information is for research and educational use only.

Tri-Heal is a research peptide blend combining TB-500 (25 mg), BPC-157 (10 mg), and KPV (10 mg) for advanced tissue repair and inflammation modulation. TB-500 is a synthetic fragment of thymosin β4, a 43-amino-acid peptide involved in cell migration, angiogenesis, and wound healing. BPC-157 is a synthetic 15-amino-acid body protection compound with pro-angiogenic and gastroprotective properties. KPV (Lys-Pro-Val) is a tripeptide derived from α-MSH noted for potent anti-inflammatory effects. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for accurate measurements.

Educational guide for reconstitution and daily administration

Standard 8-Week Protocol (3 mL = 15 mg/mL)

Week	Daily Amount	Units (per administration)	Volume
Weeks 1–2	500 mcg	3.3 units*	0.033 mL
Weeks 3–4	1000 mcg	6.7 units*	0.067 mL
Weeks 5–6	1500 mcg	10 units	0.10 mL
Weeks 7–8	2000 mcg	13.3 units	0.133 mL

Frequency: Administer once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to optimize measurement accuracy across all daily amounts.

Precision Note: For administrations ≤10 units (≤0.10 mL), consider using 30-unit or 50-unit measuring devices for improved readability and accuracy.

Extended 12-Week Protocol (3 mL = 15 mg/mL)

Week	Daily Amount	Units (per administration)	0.167 mL
Weeks 1–2	500 mcg	3.3 units	0.033 mL
Weeks 3–4	1000 mcg	6.7 units	0.067 mL
Weeks 5–6	1500 mcg	10 units	0.10 mL
Weeks 7–8	2000 mcg	13.3 units	0.133 mL
Weeks 9–10	2500 mcg	16.7 units	0.167 mL
Weeks 11–12	3000 mcg	20 units	0.20 mL

Extended 16-Week Protocol (3 mL = 15 mg/mL)

Week	Daily Amount	Units (per administration)	Volume
Weeks 1–2	500 mcg	3.3 units	0.033 mL
Weeks 3–4	1000 mcg	6.7 units	0.067 mL
Weeks 5–6	1500 mcg	10 units	0.10 mL
Weeks 7–8	2000 mcg	13.3 units	0.133 mL
Weeks 9–10	2500 mcg	16.7 units	0.167 mL
Weeks 11–12	3000 mcg	20 units	0.20 mL
Weeks 13–14	3500 mcg	23.3 units	0.233 mL
Weeks 15–16	4000 mcg	26.7 units	0.267 mL

Reconstitution Steps

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8–16 week daily protocol with gradual titration.

Per week: 7 administration devices (1/day)
8 weeks: 56 administration devices
12 weeks: 84 administration devices
16 weeks: 112 administration devices
Recommendation: Include 30-unit or 50-unit measuring devices for the early low-volume phases (Weeks 1–4) where precision is important.

Concise summary of the once-daily regimen.

Goal: Support tissue repair, regeneration, and inflammation modulation through synergistic peptide action.
Schedule: Daily subcutaneous administration for 8–12 weeks (extend to 16 weeks if desired).
Daily Range: 500–4000 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 45 mg vial (15 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.

Suggested daily titration approach.

Start: 500 mcg daily; increase by approximately 500 mcg every 2 weeks as tolerated.
Target: 1500–2000 mcg daily by Weeks 5–8 (standard); up to 3000–4000 mcg for extended schedules.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate administration sites systematically.

Proper storage preserves peptide quality and potency.

Lyophilized: Store at −20 °C (−4 °F) or colder (ideally −80 °C / −112 °F) in dry, dark conditions.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks; prepare aliquots if needed and avoid freeze–thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

Use a new sterile measuring device for each administration; dispose of used materials in an appropriate sharps container.
Rotate administration sites (abdomen, thighs, upper arms) to reduce local irritation and help prevent lipohypertrophy.
Administer slowly and wait a few seconds before withdrawing the needle.
Document the daily amount, administration site, and any observations to maintain consistency.
For administrations under 10 units, use 30-unit or 50-unit measuring devices for improved accuracy.

Tri-Heal combines three peptides with complementary mechanisms targeting multiple aspects of tissue injury repair.

TB-500 (Thymosin β4): Acts as a natural repair factor, inhibiting inflammation and apoptosis while promoting angiogenesis, cell migration, and matrix remodeling. This 43-amino-acid peptide has been shown to accelerate dermal healing in preclinical models and clinical applications.

BPC-157 (Body Protection Compound): Enhances healing through VEGFR2/Akt-eNOS activation, increasing nitric oxide production and angiogenesis while stimulating fibroblast activity. This 15-amino-acid gastric peptide supports tendon, muscle, and gastrointestinal tissue repair.

KPV (Lys-Pro-Val): Provides anti-inflammatory effects by reducing NF-κB activation and attenuating pro-inflammatory cytokine signaling in epithelial and immune cells. This α-MSH-derived tripeptide complements the regenerative actions of TB-500 and BPC-157.

Together, these three peptides target wound repair, angiogenesis, and inflammation through complementary mechanisms.

Observations from preclinical and clinical literature on the individual components.

Potential Benefits

TB-500: Supports cell proliferation, angiogenesis, and tissue repair while helping regulate inflammation.
BPC-157: Supports tendon, muscle, and connective tissue repair while promoting endothelial and fibroblast activity.
KPV: Helps reduce inflammatory cytokine activity and supports epithelial tissue health.
The individual components have generally been well tolerated in preclinical studies.

Common Side Effects

Complementary strategies for optimal metabolic outcomes.

Maintain adequate protein intake (1.6–2.2 g/kg body weight) to support tissue repair.
Maintain appropriate activity levels while avoiding excessive strain on healing tissues.
Prioritize 7–9 hours of quality sleep each night.
Manage stress through appropriate recovery practices.
Stay well hydrated and maintain adequate vitamin C, zinc, and collagen-supporting nutrients.

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and administration site with alcohol and allow both to dry completely.
Pinch a skin fold and insert the needle at a 45–90° angle into subcutaneous tissue.
Do not aspirate during subcutaneous administration; administer slowly and steadily.
Rotate administration sites systematically (abdomen, thighs, upper arms) to reduce tissue irritation.
Rotate administration areas systematically (abdomen preferred; also thighs, upper arms) to avoid lipohypertrophy.
Dispose of used administration devices immediately in an approved sharps container; never reuse needles.

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. For research use only. Not for human consumption.

Annals of the New York Academy of Sciences (2012)

— The regenerative peptide thymosin β4 accelerates dermal healing in preclinical models and patients.

HSS Journal / PMC (2025)

— Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.

Molecular Therapy Methods & Clinical Development / PMC (2017)

— Orally Targeted Delivery of Tripeptide KPV via HA-Functionalized Nanoparticles Alleviates Ulcerative Colitis

Clinical Chemistry (2016)

— Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays

CDC Pink Book (2024)

— Vaccine Administration: subcutaneous route technique, angle, and site guidance

Frontiers in Endocrinology (2021)

— Progress on the Function and Application of Thymosin β4

Current Reviews in Musculoskeletal Medicine (2025)

— Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing

Journal of Orthopaedic Research (2003)

— Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and stimulates tendocyte growth

CDC (Subcutaneous Administration PDF)

— Technique diagram and site guidance for subcutaneous administration

NCBI Bookshelf

— Best practices for parenteral administration: asepsis, preparation, and administration

Subcutaneous Administration Review / PMC

— Pharmacologic considerations of the subcutaneous route